Brokers Offer Predictions for 89bio FY2025 Earnings

89bio, Inc. (NASDAQ:ETNB) – Equities research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of 89bio in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($1.88) per share for the year, up from their previous estimate of ($2.44). Cantor Fitzgerald has a “Overweight” rating and a $29.00 price target on the stock. The consensus estimate for 89bio’s current full-year earnings is ($3.19) per share.

Several other research analysts also recently commented on ETNB. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target (down from $29.00) on shares of 89bio in a research report on Friday, February 28th. Raymond James raised 89bio to a “strong-buy” rating in a research report on Thursday, December 12th. Wolfe Research initiated coverage on 89bio in a research report on Tuesday, February 4th. They issued an “outperform” rating on the stock. UBS Group lifted their price target on 89bio from $25.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 89bio in a research report on Friday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $30.29.

89bio Stock Performance

Shares of NASDAQ ETNB opened at $7.85 on Thursday. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average is $8.80 and its two-hundred day moving average is $8.48. The company has a market cap of $833.09 million, a P/E ratio of -2.70 and a beta of 1.17. 89bio has a 12 month low of $5.99 and a 12 month high of $13.71.

89bio (NASDAQ:ETNB) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.42).

Hedge Funds Weigh In On 89bio

Large investors have recently made changes to their positions in the company. Federated Hermes Inc. lifted its stake in shares of 89bio by 206.9% during the fourth quarter. Federated Hermes Inc. now owns 6,283 shares of the company’s stock valued at $49,000 after acquiring an additional 4,236 shares during the period. Quarry LP acquired a new position in shares of 89bio during the fourth quarter valued at $55,000. Kingswood Wealth Advisors LLC acquired a new position in shares of 89bio during the fourth quarter valued at $86,000. Sandia Investment Management LP lifted its stake in shares of 89bio by 28.5% during the fourth quarter. Sandia Investment Management LP now owns 11,286 shares of the company’s stock valued at $88,000 after acquiring an additional 2,500 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in shares of 89bio during the fourth quarter valued at $87,000.

Insider Activity at 89bio

In other 89bio news, insider Quoc Le-Nguyen sold 10,963 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $6.49, for a total value of $71,149.87. Following the transaction, the insider now owns 271,833 shares of the company’s stock, valued at approximately $1,764,196.17. The trade was a 3.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Charles Mcwherter acquired 5,000 shares of 89bio stock in a transaction on Tuesday, January 21st. The stock was acquired at an average cost of $6.55 per share, for a total transaction of $32,750.00. Following the purchase, the director now owns 15,000 shares of the company’s stock, valued at approximately $98,250. This represents a 50.00 % increase in their position. The disclosure for this purchase can be found here. 2.80% of the stock is owned by insiders.

89bio Company Profile

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.